18F-Flortaucipir PET视觉读图法在阿尔茨海默病连续体及路易体痴呆中的表现
在阿姆斯特丹大学医学中心纳入263名参与者,评估18F-flortaucipir PET视觉读图法的可靠性、与半定量分析的一致性及与临床变量的关联。读图者间一致性极佳(κ=0.95),与SUVr状态高度一致(最高90.4%),视觉读图tau阳性与认知下降相关。
要点
- 视觉读图者间一致性极佳(κ=0.95,CI 0.91-0.99)。
- 视觉读图与SUVr状态高度一致,最高达90.4%。
- 视觉读图tau阳性与CU及AD参与者的MMSE下降相关。
核心结论
- 视觉读图法可靠性高、稳健,支持临床应用,且tau阳性与前瞻性认知下降相关,具有额外预后潜力。
- 未来需在未选择队列中研究以提高对临床人群的普遍性。
研究设计与样本
- 在阿姆斯特丹大学医学中心纳入接受tau-PET的参与者,部分进行随访tau-PET,两名受训核医学医师视觉评估所有扫描。
- 共纳入263名参与者(平均年龄68.5岁,45.6%女性),包括147名认知未受损(CU)、97名淀粉样蛋白阳性轻度认知障碍或AD痴呆(AD)及19名路易体痴呆(DLB)参与者。
主要发现
- 读图者间一致性极佳(κ=0.95,CI 0.91-0.99)。
- 淀粉样蛋白阴性CU参与者中0/92(0%)为tau阳性,淀粉样蛋白阴性DLB参与者中1/12(8.3%)为tau阳性。
- 淀粉样蛋白阳性参与者中,CU 13/52(25.0%)、AD 85/97(87.6%)、DLB 3/7(42.9%)为tau阳性。
- 两年随访视觉读图状态与基线相同。
- 视觉读图与SUVr状态高度一致,最高达90.4%。
关键数值与推荐
- 视觉读图者间一致性κ=0.95(CI 0.91-0.99)。
- 视觉读图与SUVr状态一致性最高90.4%。
- CU参与者MMSE下降β=-0.52(CI -0.74至-0.30,p<0.001);AD参与者β=-0.30(CI -0.58至-0.02,p=0.04)。
临床怎么用
- 视觉读图法可靠且与半定量分析高度一致,支持临床应用。
- 视觉读图tau阳性与认知下降相关,具有额外预后潜力。
局限性
- 未来需在未选择队列中研究以提高对临床人群的普遍性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVES: Recently, the US Food and Drug Administration approved the tau-binding radiotracer [18F]flortaucipir and an accompanying visual read method to support the diagnostic process in cognitively impaired patients assessed for Alzheimer disease (AD). Studies evaluating this visual read method are limited. In this study, we evaluated the performance of the visual read method in participants along the AD continuum and dementia with Lewy bodies (DLB) by determining its reliability, accordance with semiquantitative analyses, and associations with clinically relevant variables. METHODS: We included participants who underwent tau-PET at Amsterdam University Medical Center. A subset underwent follow-up tau-PET. Two trained nuclear medicine physicians visually assessed all scans. Inter-reader agreement was calculated using Cohen κ. To examine the concordance of visual read tau positivity with semiquantification, we defined standardized uptake value ratio (SUVr) positivity using different threshold approaches. To evaluate the prognostic value of tau-PET visual read, we performed linear mixed models with longitudinal Mini-Mental State Examination (MMSE). RESULTS: We included 263 participants (mean age 68.5 years, 45.6% female), including 147 cognitively unimpaired (CU) participants, 97 amyloid-positive participants with mild cognitive impairment or AD dementia (AD), and 19 participants with DLB. The visual read inter-reader agreement was excellent (κ = 0.95, CI 0.91-0.99). None of the amyloid-negative CU participants (0/92 [0%]) and 1 amyloid-negative participant with DLB (1/12 [8.3%]) were tau-positive. Among amyloid-positive participants, 13 CU participants (13/52 [25.0%]), 85 with AD (85/97 [87.6%]), and 3 with DLB (3/7 [42.9%]) were tau-positive. Two-year follow-up visual read status was identical to baseline. Tau-PET visual read corresponded strongly to SUVr status, with up to 90.4% concordance. Visual read tau positivity was associated with a decline on the MMSE in CU participants (β = -0.52, CI -0.74 to -0.30, p < 0.001) and participants with AD (β = -0.30, CI -0.58 to -0.02, p = 0.04). DISCUSSION: The excellent inter-reader agreement, strong correspondence with SUVr, and longitudinal stability indicate that the visual read method is reliable and robust, supporting clinical application. Furthermore, visual read tau positivity was associated with prospective cognitive decline, highlighting its additional prognostic potential. Future studies in unselected cohorts are needed for a better generalizability to the clinical population. CLASSIFICATION OF EVIDENCE: This study provides Class II evidence that [18F]flortaucipir visual read accurately distinguishes patients with low tau-tracer binding from those with high tau-tracer binding and is associated with amyloid positivity and cognitive decline.
引用
- Coomans EM, de Koning LA, Rikken RM, et al. Performance of a [18F]Flortaucipir PET Visual Read Method Across the Alzheimer Disease Continuum and in Dementia With Lewy Bodies. Neurology. 2023. PMID: 37748892. doi:10.1212/WNL.0000000000207794
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。